On the origins of three-dimensionality in drug-like molecules. by Meyers, J et al.
FutureMedicinalChemistry 
Research Article
part of
On the origins of three-dimensionality in 
drug-like molecules
Joshua Meyers1,  
Michael Carter1, N Yi Mok*,1  
& Nathan Brown**,1
1Cancer Research UK Cancer 
Therapeutics Unit, Division of Cancer 
Therapeutics, The Institute of Cancer 
Research, London, SM2 5NG, UK 
*Author for correspondence:  
Yi.Mok@icr.ac.uk 
**Author for correspondence:  
Nathan.Brown@icr.ac.uk
1753Future Med. Chem. (2016) 8(14), 1753–1767 ISSN 1756-891910.4155/fmc-2016-0095 © Joshua Meyers, Michael Carter,  
        N Yi Mok & Nathan Brown
Future Med. Chem.
Research Article 2016/08/30
8
14
2016
Aim: Many medicinal chemistry-relevant structures and core scaffolds tend toward 
geometric planarity, which hampers the optimization of physicochemical properties 
desirable in drug-like molecules. As challenging drug target classes emerge, the 
exploitation of molecular three-dimensionality in lead optimization is becoming 
increasingly important. While recent interest has emphasized the importance of 
enhanced three-dimensionality in molecular fragment designs, the extent to which 
this is required in core scaffolds remains unclear. Materials & methods: Three 
computational methods, Scaffold Tree deconstruction, Synthetic Disconnection Rules 
retrosynthetic deconstruction and virtual library enumeration, are applied, together 
with the descriptors plane of best fit and principal moments of inertia, to investigate 
the origins of three-dimensionality in drug-like molecules. Conclusion: This study 
informs on the stage at which molecular three-dimensionality should be considered 
in drug design.
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The modulation and optimization of molec-
ular properties are the essence of molecular 
design in medicinal chemistry. Many dif-
ferent parameters are convoluted in bring-
ing a drug to market, neatly encapsulated 
in the safety and therapeutic efficacy of the 
drug product. The obvious properties such 
as potency against a biological target can 
be optimized in a variety of ways, but other 
characteristics of a given molecule may be 
subtly influenced by the modulation of an 
array of molecular properties through mul-
tiobjective optimization [1]. Recently, the 
three-dimensionality of chemical structures, 
from molecular fragments to drug-like mol-
ecules, has gained widespread attention 
due to reported evidence of key benefits 
to increased three-dimensionality in drug 
molecules [2–5].
An increase in the probability of clinical 
success has been implicated in the three-
dimensionality of molecules through various 
descriptors including shadow indices [6] and 
the complexity descriptor, fraction of sp3-
hybridized carbons [7]. More recently, it has 
also been shown that an increase in complex-
ity using fraction of sp3-hybridized carbons 
can lead to a reduction in promiscuity and 
CYP450 inhibition [8].
The shape of chemical structures in drug 
discovery is a crucial component for evoking 
molecular recognition events with biologi-
cal targets [9]. Natural products often contain 
enhanced three-dimensionality in their struc-
tures reflecting the interactions necessary with 
their biological partners [10]. Protein–protein 
interactions, a challenging target class that 
remains difficult to drug, are recognized as 
SPECIAL FOCUS y Computational chemistry & computer-aided drug discovery – Part I
For reprint orders, please contact reprints@future-science.com
Figure 1. Schematic illustrations of the molecular descriptors used to characterize molecular three-dimensionality. (A) Schematic 
of the principal moments of inertia ternary plot with exemplar points elaborated with their respective chemical structures. (B) The 
plane of best fit for cyclohexane (above) and an exemplar drug-like molecule (below). The plane of best fit descriptor is the average 
distance of each heavy atom from the plane of best fit through all heavy atoms.
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requiring enhanced three-dimensionality in the recently 
documented development of small molecule therapeutics. 
For example, the published inhibitors for BRD4/chro-
matin [11], LEDGF/p75 integrase [12], Bcl2/Bcl-xL fam-
ily proteins [13] and the MDM2/p53 interaction [14], 
all exhibit enhanced 3D shape to complement their 
re spective protein–protein interaction binding sites.
Physicochemical properties may also be enhanced to 
overcome particular challenges in drug design. Aque-
ous solubility of molecules is important for appropriate 
systemic exposure. Solubility may be improved by con-
sideration of the 3D shape of molecules, with improve-
ments in solubility achieved through disrupting the pla-
narity of the molecular structures leading to disruption 
within solid state crystal lattice packing [15,16].
A number of molecular descriptors have been 
reported to characterize the three-dimensionality of 
molecular structures [17]. Here, we apply two recently 
published and widely adopted molecular descriptors to 
characterize three-dimensionality of molecular struc-
tures: principal moments of inertia (PMI) [18] and plane 
of best fit (PBF) [19]. While other molecular descriptors 
of three-dimensionality have been reported, we focus on 
these two as recently reported descriptors of relevance 
for our purposes.
The PMI descriptors provide a means of assessing 
the extent to which a given molecular geometry is rod 
shaped, disc shaped and sphere shaped. The PMI are 
normally visualized on a ternary plot (Figure 1A) where 
the top-left vertex represents purely rod shaped, the 
vertex at the bottom represents those molecules that 
are completely disc shaped and the top-right vertex 
those structures that are entirely sphere shaped. There-
fore, a molecular structure of particular shape will lie 
somewhere on the continuum between those three ver-
tices representing the degree to which its morphology 
exhibits those primitive shape classes. A key character-
istic of the normalized PMI descriptors is that there 
is no size dependence, therefore, for instance, ada-
mantane and buckminsterfullerene exhibit identical 
normalized PMI ratios.
The PBF descriptor is a recent three-dimensionality 
descriptor that was designed, implemented and first 
reported in the literature by Firth et al. [19]. Given a 
particular molecular geometry, PBF identifies the 
plane of best fit running through that molecule that 
minimizes the distance of heavy atoms from the plane 
in Å. In this way, PBF is analogous to simple linear 
line-fitting in two dimensions, but extends its calcu-
lation to three dimensions. Once the plane of best 
fit has been determined, the PBF descriptor is calcu-
lated as the sum of the distances of the heavy atoms 
from the plane divided by the number of heavy atoms 
(Figure 1B). In contrast to the PMI descriptors above, 
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the PBF descriptor does exhibit size dependency in its 
calculation. Therefore, adamantane and buckminster-
fullerene will have substantially different PBF values 
– 0.79 and 1.76 Å, respectively.
In this paper we report on the origins of three-
dimensionality in drug-like molecules through analy-
sis of more than one million chemical structures that 
have been published in the medicinal chemistry litera-
ture available from the ChEMBL 21 database [20]. The 
ChEMBL contains the chemical structures of com-
pounds that have been tested and reported in experi-
mental assays and are therefore considered inherently 
drug-like. Three methods were applied to investigate 
molecular substructures of these molecules, a well-
established scaffold-based deconstruction technique, 
a previously reported retrosynthetic disconnection 
approach and a prospective analysis of new molecular 
structures enumerated in silico.
The first approach uses the published Scaffold Tree 
to systematically deconstruct molecules using the ring-
focused disconnection rules implemented in the Scaf-
fold Tree [21]. For a given molecule, pendant ring sys-
tems are pruned iteratively, generating different levels 
of the Scaffold Tree. At each level, the three-dimen-
sionality of the scaffold can be evaluated and allows for 
the retrospective understanding of the possible origins 
of three-dimensionality in drug-like molecules.
In addition to the Scaffold Tree method, it is pos-
sible to use the recently reported Synthetic Disconnec-
tion Rules (SynDiR) protocol to deconstruct chemical 
structures. Applying SynDiR to the ChEMBL drug-
like dataset renders chemically plausible substructures 
according to a prioritized list of retrosynthetic discon-
nection rules [22]. The SynDiR approach attempts to 
simulate a retrosynthetic analysis of an expert medici-
nal chemist. The three-dimensionality of the resultant 
molecular substructures can then be analyzed using 
the three-dimensionality descriptors described above.
Last, the virtual enumeration of new molecular 
structures can be used to understand how the three-
dimensionality of the enumerated molecules may 
originate from the original molecular scaffolds. Simu-
lating the prospective exploration of chemical space in 
medicinal chemistry when optimizing multiple param-
eters, the enumeration from scaffolds of varying inher-
ent three-dimensionality allows us to investigate the 
contribution to three-dimensionality from the origi-
nal scaffold versus those from the combination of the 
molecular substructures as an emergent phenomenon.
Using the two molecular descriptors of three-dimen-
sionality and the three different approaches to investi-
gate the exemplified drug-like chemistry space of inter-
est, it is possible to systematically examine the origins 
of three-dimensionality in drug-like molecules. While 
we are aware that chemical structures are often capable 
of adopting multiple conformations [23,24], hence likely 
affecting the associated descriptors of three-dimen-
sionality, the study presented here applies a literature 
standard method that evaluates the 3D geometries of 
both molecules and their substructures using a single 
CORINA-derived conformation [25]. Through these 
structural analyses, guidance can be provided on the 
origins of three-dimensionality in drug-like molecules. 
Furthermore, a thorough understanding of the best 
approaches to introduce three-dimensionality will be 
of significant benefit to modern drug discovery and 
future medicinal chemistry design.
Materials & methods
Preparation of the ChEMBL database
From ChEMBL21 [26], 1,051,579 drug-like small mol-
ecules satisfying Lipinski’s rule-of-five [27] with a mini-
mum of one ring were used in this study. In order to 
compile this dataset, 1,560,490 unique structures from 
ChEMBL21 were annotated as ‘small molecule’. Struc-
tures containing any macrocyclic ring (defined as ring 
size of 12 atoms or larger [28]) were then removed. After 
stripping salts and removing duplicates, 1,459,372 
structures remained for further analysis. The remain-
ing 1,438,214 structures were subjected to Lipinski 
Filters [27] as implemented using Pipeline Pilot [29]. The 
final dataset of drug-like small molecules contained 
1,051,579 structures.
Conformer generation
CORINA [30] was used to generate coordinates for a 
single low-energy 3D conformation of each molecule 
in the ChEMBL21 dataset [31]. Hydrogens were added 
for structure generation and subsequently removed for 
all further analysis [25]. CORINA was employed with 
default parameters apart from the ‘canon’ flag, which 
was set to False. CORINA failed to generate 3D coor-
dinates for 2411 molecules, over 90% of which were 
found to contain either chiral bridgehead atoms or a 
chiral center adjacent to a double-bonded p-system. 
Where molecules from ChEMBL21 contained unde-
fined stereocenters, these were not enumerated to avoid 
biasing the dataset toward structures with multiple 
undefined stereocenters. Instead, CORINA selects 
an arbitrary stereoisomer unless the stereocenter 
forms part of a ring in which case the lowest energy 
conformation is selected.
Calculation of 3D descriptors
All 3D descriptors were calculated from a single 
CORINA-generated low energy conformer of each 
chemical structure with hydrogens removed. The 
PMI values were calculated using the built-in protocol 
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PMI implemented in Pipeline Pilot [29]. The normal-
ized PMIs were calculated from the original PMI_X, 
PMI_Y and PMI_Z descriptors automatically in this 
component, yielding NPR1 and NPR2. The PBF 
descriptor was calculated as implemented in Python as 
part of the RDKit API (version 2015.09.02) [32].
Generation of the Scaffold Tree
The curated ChEMBL21 dataset was analyzed using 
the Scaffold Tree method as implemented in the 
Molecular Operating Environment [33]. This analysis 
resulted in 3,211,860 individual levels from 1,051,579 
unique molecular structures. The individual levels 
generated from each molecule were then opened in 
Pipeline Pilot [29] and the molecular structures gener-
ated from the SMILES strings, resulted in the failure 
of 220 levels. The remaining 3,211,640 levels were 
merged on their SMILES strings giving a total of 
384,531 unique levels of the Scaffold Tree with their 
frequency of occurrence retained. A single low-energy 
conformation for each of these Scaffold Tree levels was 
generated using CORINA [30] and hydrogen atoms 
explicitly removed after generation – 98 levels failed 
conformer generation.
Molecular deconstruction using SynDiR
SynDiR was implemented using Python and the 
RDKit API (version 2015.03.1) [32]. SMILES strings 
for 1,051,579 chemical structures in the curated 
ChEMBL21 dataset were deconstructed into 3,304,410 
substructures. Duplicate substructures were merged 
using the Merge Molecules component in Pipeline 
Pilot [29]. Disconnection points for each substructure 
were retained separately. A single low-energy confor-
mation was then generated for each substructure using 
CORINA [30] – 12 substructures failed conformer 
generation.
Enumeration of virtual libraries
•	 Core Scaffolds: exemplar core scaffolds were 
selected from the Level 1 Scaffolds with attach-
ment point annotations using the Scaffold Tree 
component as implemented in Pipeline Pilot [29]. 
Level 1 Scaffolds were binned into defined PBF 
bins of width 0.1 Å. The most frequent unique 
Level 1 Scaffold containing only two attachment 
points was selected for PBF bins ranging from 0.0 
to 0.8 Å;
•	 Terminal substituents: the twenty most frequent 
terminal substituents containing only one attach-
ment point from the unique SynDiR molecular sub-
structures were selected (Supplementary Figure 1);
•	 Libraries enumeration: the virtual libraries were 
enumerated using the selected core scaffolds and 
terminal substituents applying the built-in proto-
col Enumerate using RGroups in Pipeline Pilot [29]. 
The twenty selected terminal substituents were 
attached to each of the two attachment points on 
each individual core scaffold, resulting in a total of 
400 molecules per Level 1 scaffold.
Principal moments of inertia plots
Normalized PMI ratios were used to calculate rod-
likeness, disc-likeness and sphericity as defined by 
Wirth et al. [34]. The three PMI of a molecular geom-
etry are calculated through diagonalization of the 
moment of inertia tensor. These initial descriptors are 
normalized by dividing the two lower values by the 
highest value, yielding two mass-independent normal-
ized PMI ratios, NPR1 and NPR2, which can then 
be visualized in two dimensions – these normalized 
values are referred to as the PMI descriptors of a mol-
ecule. These were then used to plot ternary scatter and 
density plots implemented in Python making use of 
the python-ternary library [35]. An IPython Jupyter 
Notebook for creating ternary density plots is provided 
in the Supplementary Information.
Results & discussion
A concept that has persisted in the field of medici-
nal chemistry is that the coverage of chemical space 
tends toward more planar molecules at the expense 
of increased three-dimensionality. This trend can 
be explicated through appropriate descriptors of 
three-dimensionality; where more planar molecules 
are represented by the rod-shaped and disc-shaped 
edge of PMI space, and a PBF value closer to zero. 
Figure 2A shows the PMI plot for the entirety of the 
ChEMBL drug-like chemistry space illustrating that 
these molecules do indeed tend toward more planar 
geometries – those lying close to the rod-shaped and 
disc-shaped edge – with a marked preponderance of 
rod-shaped molecules. Similarly, an investigation of 
the PBF distributions for the same ChEMBL drug-
like space (Figure 2B) illustrates that the median of the 
PBF distribution is approximately 0.6 Å, over a wider 
range from 0 to 2 Å. This clear over-representation at 
the lower end of the range of the PBF values suggests 
that while molecular structures with enhanced three-
dimensionality are possible and have been investigated, 
the majority of chemical structures reduced to practice 
through synthesis have a tendency away from more 3D 
space.
Analyses of both the PMI and PBF distributions 
of three-dimensionality from the ChEMBL drug-like 
dataset illustrate that, while enhanced 3D shape has 
Figure 2. The three-dimensionality profile of the ChEMBL drug-like chemistry space analyzed throughout this study (n = 1,045,172). 
(A) The PMI ternary density plot and (B) the PBF box-and-whisker plot (in Å). The color key conveys the density of molecules in each 
bin of the ternary plot. 
PBF: Plane of best fit; PMI: Principal moments of inertia.
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been reported in the literature, these chemical struc-
tures tend to be under-represented (Figure 2). While 
it is possible to speculate on reasons for this observed 
lack of 3D structures, such as conventions of synthe-
sis or biological necessity [36], it is impossible to truly 
isolate the reasons for this observed imbalance. How-
ever, it is possible to investigate further the origins of 
three-dimensionality in drug-like molecular struc-
tures through observation of structures that exist and 
those that could exist through unbiased virtual library 
enumeration.
The parent molecule analysis of the chemical struc-
tures in the ChEMBL drug-like dataset, summarized 
in Figure 2, demonstrates a general lack of shape diver-
sity and three-dimensionality. However, this does not 
inform on the origins of three-dimensionality in drug-
like molecules, rather the ultimate designs that are syn-
thesized. Therefore, the question remains open: from 
where does three-dimensionality originate in drug-like 
molecules. Using the Scaffold Tree algorithm [21] it is 
possible to apply systematic disconnection rules to pare 
back the parent molecules to their constituent scaffolds, 
ring-by-ring. The application of the Scaffold Tree algo-
rithm to the parent molecules in the ChEMBL drug-
like dataset is presented with both the PMI (Figure 3A) 
and PBF (Figure 3B) distributions.
The ternary density plots of the PMI values 
(Figure 3A) illustrate the density of individual scaffolds 
from level 8 (where present) down to level 0 in decreas-
ing number of rings, where level 0 scaffolds contain 
a single ring by definition. The color key conveys the 
density of individual scaffolds in each bin of the ternary 
plot, and is logarithmically scaled (note the dramatic 
frequency changes between each level when interpret-
ing these figures). The higher levels of the Scaffold 
Tree are sparse since there are relatively few individual 
scaffolds with many rings (Figure 3C displays the num-
ber of scaffolds generated for each level of the Scaf-
fold Tree for the entire ChEMBL drug-like dataset). 
As the Scaffold Tree levels are reduced, shifts toward 
more planar regions of PMI space can be observed. 
This reduction in overall three-dimensionality is even 
more pronounced in the box-and-whisker plot of the 
PBF distributions for the individual Scaffold Tree lev-
els when compared with the original parent molecules 
(Figure 3B). The general trend is consistently toward 
more planar scaffolds as the size of the scaffolds is 
reduced.
In a recent publication on the scaffold diversity of 
exemplified medicinal chemistry [37], it was observed 
that Level 1 of the Scaffold Tree typically represents an 
appropriate objective and invariant scaffold definition. 
With this definition in mind, it can be observed clearly 
that there is a substantial reduction in three-dimen-
sionality when a drug-like molecule is reduced to its 
molecular scaffold, in particular between the Level 2 
and Level 1 scaffolds where the median value of PBF 
distributions decreases from 0.37 Å for Level 2 scaf-
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Figure 3. The three-dimensionality profile of the individual Scaffold Tree levels (see facing page). (A) The PMI ternary density plots 
and (B) the PBF box-and-whisker plot (in Å). The color key conveys the density of individual scaffolds in each bin of the ternary plot. 
The table in (C) shows the number of structures contained within each Scaffold Tree level. (B) also includes the PBF box-and-whisker 
for the parent structures from ChEMBL for comparison; the equivalent PMI plot is shown in Figure 2A. 
PBF: Plane of best fit; PMI: Principal moments of inertia.
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folds to 0.11 Å for Level 1 scaffolds (Figure 3B). This 
observation implies that many drug-like molecules 
in ChEMBL have been derivatized from molecular 
scaffolds that are relatively planar. Another striking 
observation is the shift from rod-shaped to disc-shaped 
structures between the Level 1 and level 0 scaffolds in 
the Scaffold Tree. These phenomena can be explained 
by the prevalence of bicycles and monocycles in these 
two levels, respectively.
Using the Level 1 scaffold definition, it is pos-
sible to identify exemplified patterns of derivatization 
using their representatives from the ChEMBL drug-
like dataset. This analysis can be used to understand 
the extent to which the three-dimensionality of the 
scaffolds may contribute to the overall three-dimen-
sionality of the parent molecules. Figure 4 illustrates 
eight exemplar core scaffolds with increasing three-
dimensionality selected as the most frequent disubsti-
tuted Level 1 scaffolds from eight uniformly divided 
PBF bins, ranging from 0 to 0.8 Å. The most frequent 
disubstituted Level 1 scaffolds in the higher PBF bins 
above 0.8 Å represent only a small number of parent 
molecules, hence those were not further analyzed. The 
ternary plots and box-and-whisker plots show the PMI 
and PBF distributions for each core scaffold, respec-
tively. The ternary plots report the PMI of the core as 
a black star and every parent molecule containing that 
core as red points. The PBF values are reported in the 
box-and-whisker plots with the PBF value of the core 
on the left and the PBF distributions of the parents 
containing those cores on the right.
Figure 4 demonstrates that it is possible to modulate 
the three-dimensionality of parent molecules designed 
around a common scaffold regardless of the local 
three-dimensionality of the core scaffold itself, albeit 
to different degrees. Cores A and B, for example, while 
representing the two most planar scaffolds, are present 
in parent molecules that show broad sampling of PMI 
space. The rod-shaped tendency of the parent mole-
cules from cores C and E can be partially explained by 
the linear substitution patterns of those scaffolds; this 
derivatization pattern has been recently shown to pro-
mote rod-likeness in PMI space [36]. Core D, although 
arguably a reasonable medicinal chemistry starting 
point, exhibits poor exploration of 3D space, tend-
ing mainly toward rod-shaped space, and not explor-
ing toward the sphere-shaped vertex at all. Further-
more, all reported parent molecules containing Core 
F, an example of a sphere-shaped bridged ring scaf-
fold, represent a relative reduction in their sphericity. 
This observation highlights the potential limit of the 
exploration of 3D shape space of an exemplar-bridged 
scaffold that may otherwise be expected to promote 
three-dimensionality in exemplified derivatives. Across 
all PBF bins, the median of the PBF distributions for 
the parent structures can be seen to converge to a simi-
lar range of values irrespective of the PBF value of the 
originating core scaffold.
This retrospective experiment analyzing exemplified 
core scaffolds and their derivatized parents from the 
ChEMBL drug-like dataset suggests that, based on our 
analysis, there is no clear rationale for increasing the 
complexity or three-dimensionality of core scaffolds 
for an enhancement in the three-dimensionality of the 
parent molecules. It is the connectivity of the substruc-
tures that appears to contribute the most to the three-
dimensionality of the parent molecules, rather than the 
local three-dimensionality of the core substructures 
themselves. Therefore, it can be concluded from this 
analysis that 3D molecules can be constructed from 
2D core scaffolds and substructures.
While the retrospective experiment exemplified 
in Figure 4 provided some plausible insights into the 
origins of three-dimensionality of existing molecules 
from the ChEMBL drug-like dataset, it does represent 
a biased dataset subject to the requirements of different 
drug design projects at different times and the extent 
that a core scaffold has been explored synthetically. 
However, using the common core scaffolds selected 
in that experiment, an objective study can be devised 
that enumerates virtual libraries for each of the core 
scaffolds with the same substituents. To achieve this, it 
is necessary to identify common terminal substituents 
present in drug-like molecules. Therefore, using the 
ChEMBL drug-like dataset, the set of substructures 
present has been mined using a recently published set 
of retrosynthetic disconnection rules, SynDiR [22]. 
This set of SynDiR-generated substructures can also 
be assessed in parallel to the Scaffold Tree output, 
reducing possible biased observations from a single 
deconstruction algorithm.
Figure 5 illustrates the three-dimensionality of the 
SynDiR-generated substructures derived from the 
ChEMBL drug-like dataset. Figure 5A shows the ter-
nary density plot representing the PMI values of the 
actual frequency of occurrence of each substructure in 
the dataset, while Figure 5B shows the unique occur-
rence of each substructure with all duplicates removed. 
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From both figures it is possible to recognize that 
there is a prevalence of substructures that are inclined 
toward the rod-shaped to disc-shaped edge and there-
fore exhibit strong planarity. When considering the 
frequency of occurrence (Figure 5A) and the unique 
occurrences (Figure 5B), the substructure morphology 
can be seen to shift toward enhanced three-dimension-
ality. This observation highlights that, while there is 
precedence for more 3D substructures, these are not 
represented well in their actual occurrence in exempli-
fied medicinal chemistry. This observation agrees with 
previous evidence reported here from the Scaffold Tree 
analysis (Figure 3) that suggests, while substructures 
with enhanced three-dimensionality are present in the 
output of synthetic medicinal chemistry, they are not 
highly represented in the actual chemical structures 
synthesized and reported in the literature.
The PBF values for the SynDiR-generated substruc-
tures are given in Figure 5C as a 2D density heat map, 
with the logarithm of the actual frequency of occur-
rence on the x-axis and the PBF on the y-axis. This 
figure reinforces the conclusion from Figure 5A that 
there are many different planar substructures and that 
they occur very frequently in medicinal chemistry 
space whereas 3D substructures with high PBF val-
ues are sparsely represented. Similarly, Figure 5D illus-
trates the relationships between the actual frequency of 
occurrence of substructures, the unique substructures 
and the original parent structures from the ChEMBL 
drug-like dataset. This box-and-whisker diagram reit-
erates the prevalence of planar substructures that are 
commonly assembled in medicinal chemistry even 
though available 3D substructures have been sampled.
Analysis of the constituent substructures used in 
medicinal chemistry exemplified in the literature dem-
onstrates that most of the chemistry space covered 
tends away from three-dimensionality in practice. 
Given the analysis of the scaffolds, in particular the 
Level 1 scaffolds, and the constituent substructures 
exemplified, it is now possible to repeat the experi-
ments reported in Figure 4. However, rather than 
investigating the three-dimensionality of core scaf-
folds and their exemplars in the ChEMBL drug-like 
dataset, the most common core scaffolds of defined 
three-dimensionality, together with the most com-
mon terminal substituents, were used to objectively 
enumerate a virtual library containing core scaffolds of 
increasing three-dimensionality. Figure 6 presents enu-
merated virtual libraries centered on the same set of 
disubstituted Level 1 scaffolds analyzed in the previous 
experiment. The enumerated libraries use the twenty 
most common terminal substituents from the sub-
structures generated using the SynDiR retrosynthetic 
algorithm (Supplementary Figure 1); therefore the 
resultant virtual libraries vary only in the scaffold used 
in each case. The PBF values for the twenty terminal 
substituents were very low, ranging from 0 to 0.25 Å, 
reflecting the largely 2D nature of the most frequently 
occurring substructures identified in Figure 5. This 
study allows for the investigation of the contribution 
to three-dimensionality of the core scaffolds. Although 
enumerated structures may not be drug-like or even 
synthesizable, they represent an objective method with 
solid foundation for the investigation of the origins of 
three-dimensionality in chemistry space.
In many respects, the PMI plots and PBF distribu-
tions shown for each core scaffold in Figure 6 mirror 
those in Figure 4. This is reassuring and shows the 
capability of virtual library enumeration to explore 
potential chemical space surrounding these cores. The 
more planar core scaffolds in Figure 6 (Cores A and 
B) exhibit the ability to sample broad 3D shape space, 
supporting previous observations that 3D molecules 
can be constructed from 2D core scaffolds and sub-
structures (Figure 4). While the majority of the cores 
contribute positively to the three-dimensionality of 
the enumerated libraries, this increase is much more 
pronounced in the planar cores. This may in part be 
explained by the relative change in molecular size 
when substituents are attached to the core. While the 
terminal substituents have been kept constant in this 
enumeration experiment, the relative change in molec-
ular size between the core scaffold and the enumerated 
structures is larger for the planar core scaffolds of lower 
MW (for instance, MW of Core A is 118.14 Da) than 
the more 3D core scaffolds (Core H, MW 233.29 Da).
More surprisingly, the enumerated library from 
Core F displays a more localized coverage of PMI space 
in comparison to that in Figure 4, with the enumer-
ated library lacking coverage toward the disc-shaped 
vertex of PMI space. This difference might be attrib-
uted toward the more diverse substituents in exempli-
fied chemistry space than those utilized to create the 
enumerated library. Smaller substituents in combina-
tion with the linear substitution pattern of this core 
may be responsible for the preponderance of rod-
shaped molecules in the enumerated library. Nonethe-
less, in both cases Core F shows limited exploration of 
enhanced 3D shape space, once again highlighting the 
potential limit of exploration for an exemplar bridged 
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Figure 5. The three-dimensionality profile of Synthetic Disconnection Rules substructures (see facing page). (A) PMI ternary density 
plot showing the distribution of all SynDiR substructures and their frequency of occurrence (i.e., each substructure is counted the 
number of times it appears in the entire dataset) in ChEMBL (n = 2,929,923), and (B) the distribution of SynDiR substructures and their 
unique frequency of occurrence (i.e., each specific substructure is counted only once) in ChEMBL (n = 170,758). Figure (C) shows a 
heat map of, on the x-axis, the logarithm of the frequency of occurrence of SynDiR substructures in ChEMBL and, on the y-axis, their 
PBF values (in Å). The color of the heat map in figure (C) indicates the number of different substructures that occupy that particular 
bin, that is, they are similarly frequent and similar in 3D character, but are different structures. The color key conveys the density of 
individual substructures in each bin of the plots. Figure (D) is a box-and-whisker plot of all SynDiR substructures, the unique SynDiR 
substructures and the parent molecules in ChEMBL, against their respective PBF values (in Å). 
PBF: Plane of best fit; PMI: Principal moments of inertia; SynDiR: Synthetic Disconnection Rules.
www.future-science.com 1763future science group
On the origins of three-dimensionality in drug-like molecules    Research Article
scaffold that may otherwise be expected to promote 
three-dimensionality.
While the intrinsic three-dimensionality of the core 
scaffolds does not appear to contribute extensively to 
the PMI shape space coverage of the enumerated librar-
ies, comparisons of the trend in median values of the 
PBF distributions suggest more 3D core scaffolds could 
result in more 3D enumerated libraries. Although this 
observation implies that more 3D core scaffolds may 
represent a good starting point in accessing molecules 
of enhanced three-dimensionality, it is noteworthy 
that the range of the PBF distributions decreases as the 
three-dimensionality of the core increases. This trend 
recapitulates the previous analysis of exemplified struc-
tures in ChEMBL (Figure 4), which shows that explo-
ration of three dimensionality, in practice, can equally 
be accessible from planar core scaffolds.
The work presented here offers a range of interest-
ing insights into the origins of three-dimensionality 
in medicinal chemistry-relevant structures. Early in 
a drug design project, it is important to have a clear 
motivation and design ethic prior to the introduction 
of more complex 3D cores. One of the main reasons 
to consider carefully the introduction of complex 3D 
cores is the inherent challenge in their synthesis and 
derivatization. Careful thought is required with regard 
to the potential improvements, such as physicochemi-
cal properties and improved intellectual property posi-
tion, at the cost of effective exploration and exploita-
tion of the chemistry space accessible through available 
synthetic methodologies. The probability of finding 
leads may also decrease as the molecular complexity of 
the core increases [38]. Similarly, the choice of substitu-
ents is important and the results presented here suggest 
that the combination of relatively planar scaffolds and 
substituents can lead to an effective sampling of 3D 
shape space.
Conclusion & future perspective
The benefits afforded by increased three-dimension-
ality in drug-like molecules, such as potency and 
enhanced physicochemical properties, have attracted 
much attention toward the exploration of novel 3D 
scaffolds and fragments. However, the origins of three-
dimensionality in drug-like molecules have remained 
largely unexplored. Here we present an investigation 
of the origins of the 3D nature of drug-like molecules 
by studying structures that exist in the ChEMBL 
database, and those that could exist through unbiased 
virtual library enumeration.
Inspection of the three-dimensionality, measured 
by both PMI and PBF, exhibited by molecules in 
the ChEMBL drug-like dataset demonstrates that 
while a wide range of three-dimensionalities has been 
reported in the literature, there is an under-represen-
tation of chemical structures displaying enhanced 
three-dimensionalities.
Deconstruction of parent molecules according to 
the Scaffold Tree algorithm highlights a trend toward 
planarity as pendant ring systems are iteratively 
removed. This trend is recapitulated when parent mol-
ecules are retrosynthetically deconstructed as defined 
by SynDiR, which exposes the propensity of medici-
nal chemistry to repeatedly incorporate largely planar 
substructures. Both deconstruction methods consis-
tently demonstrated that, while there is precedence 
for substructures of enhanced three-dimensionality, 
these are not proportionally represented by their actual 
occurrence in exemplified medicinal chemistry.
Using Level 1 scaffold definitions to investigate 
exemplar core scaffolds and their parent molecules 
in ChEMBL, analysis of the PMI and PBF distribu-
tions associated with each core scaffold revealed that 
it is possible for exemplified chemical structures to 
exhibit enhanced three-dimensionality regardless of 
the intrinsic three-dimensionality of the core scaffold. 
This has implications as this analysis suggests that 3D 
molecules can be constructed from more planar core 
scaffolds. It was also highlighted that the substitution 
pattern of the core scaffolds can have a decisive influ-
ence on the coverage of PMI space, as illustrated by 
exemplar scaffolds of linear and adjacent disubstitu-
tions. Attempts to further minimize any potential bias 
from our analysis of exemplified synthetic medicinal 
chemistry space were also investigated. Virtual library 
enumeration was employed as an unbiased method 
of probing chemical shape space accessible from core 
scaffolds of increasing three-dimensionality. These 
enumerated libraries illustrate that while core scaffolds 
of greater three-dimensionality may offer good starting 
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points for accessing 3D molecules, planar core scaf-
folds are comparably capable of sampling enhanced 
3D shape space.
In conclusion, our study of ChEMBL drug-like 
molecules and their systematically deconstructed 
substructures provides some interesting insights into 
the origins of three-dimensionality in medicinal 
chemistry space. The results presented here suggest 
that relatively planar scaffolds and substituents can 
be combined to access a reasonable sampling of 3D 
shape space. While core scaffolds of enhanced three-
dimensionality could facilitate sampling of more 3D 
shape space, we recommend that the consequences 
regarding synthetic accessibility and chemical space 
sampling of increasing 3D complexity be carefully 
considered before introducing more synthetically 
challenging 3D cores as a method of increasing 
molecular three-dimensionality.
Future perspective
While the potential benefits afforded by increased 
three-dimensionality in drug-like molecules are 
apparently multitudinous, there has been limited 
availability of objective methods evaluating molecu-
lar three-dimensionality that are easily interpretable 
when designing molecules. Using the simple descrip-
tors PMI and PBF, this analysis has highlighted the 
prevalence of planar scaffolds and substructures that 
are exemplified in drug-like molecules reported in 
the medicinal chemistry literature regardless of the 
molecular three-dimensionality of the designed mol-
ecules. The observations in this analysis suggest that 
relatively planar scaffolds and substituents can be 
combined to access a reasonable sampling of 3D shape 
space. This is encouraging since many of the synthetic 
methodologies available to medicinal chemists are 
based on aromatic heterocyclic chemistry. However, 
the lack of well-represented scaffolds and substruc-
tures with intrinsic enhanced three-dimensionality 
in drug-like molecules analyzed may reflect the con-
straints in synthetic accessibility of these inherently 
more complex building blocks. The demand for novel 
synthesis in practice would become increasingly press-
ing as medicinal chemistry and drug discovery efforts 
diverge from a focus on protein kinase inhibition to 
emerging biological target classes including epigen-
etic targets and protein–protein interactions. The 
development of systematic data mining of historical 
synthetic records in medicinal chemistry laboratories 
will assist in unveiling lesser explored synthetic meth-
odologies that may be enabled. As innovative meth-
odologies and technologies continue to emerge in the 
medicinal chemistry synthetic toolkit, the diversity of 
synthetic tools available to medicinal chemists may 
enable and encourage the construction of designed 
drug-like molecules from more 3D scaffolds and 
substructures.
Supplementary data
To view the supplementary data that accompany this paper 
please visit the journal website at: www.future-science.com/
doi/full/10.4155/fmc-2016-0095 
Executive summary
Existing drug-like molecules
•	 Existing drug-like molecules exemplified in the ChEMBL database tend toward planarity.
•	 However, a number of molecules are represented in more 3D space.
•	 3D molecules are reported but are under-represented compared with more planar structures.
Scaffold Tree analyses
•	 Molecules pared back ring by ring using the Scaffold Tree show substantial reduction in three-dimensionality.
•	 Medicinal chemistry-relevant Level 1 scaffolds are typically planar.
•	 More planar scaffolds tend to permit greater modulation of molecular three-dimensionality.
Retrosynthetic analyses
•	 Retrosynthetic analysis conducted using Synthetic Disconnection Rules to deconstruct molecules to 
synthetically relevant substructures.
•	 Most substructures tend toward planarity.
•	 More 3D substructures do exist, but are used very rarely in practice.
Virtual library enumeration
•	 Virtual libraries can be enumerated from previously identified medicinal chemistry-relevant scaffolds and 
derived substructures.
•	 Greater modulation in three-dimensionality is possible when starting from planar scaffolds.
•	 However, more 3D scaffolds can facilitate sampling of more 3D shape space.
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